Interpace Biosciences Inc is a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and multiple pathology services for improved patient diagnosis and management.
This Company today announces the clinical validation data for its thyroid cancer test platform, which consists of a mutation panel and a microRNA risk classifier. The new data demonstrated the addition of miRNA pairwise expression profiling that provides the clinical and statistically superior risk of stratification in determining the thyroid nodules.
Besides providing the IDXG Stock, the algorithmic classification analysis provides the original thyraMIR assay. Moreover, the ThraMIRv2 was developed and validated in a full-blinded cohort from a previous retrospective validation of the study.
The new data analysis revealed the improvements in the number of actual negative results and the reduction in the false positive results with a subsequent improvement in the specificity and PPC at the positive threshold. They also present high sensitivity and NPV.
The chief scientific officer of interface diagnostic commented that the analysis might also reduce the risk of RNA sampling error because miRNAs can migrate throughout the thyroid nodule. As a result, they may be less affected by spatial variability than the distribution of cells with DNA and mutation.
About Interpace Biosciences:
Besides providing IDXG Stock, Interpace Biosciences is an emerging leader that enables personalized medicine and offers specialized services along the therapeutic value chain. Also, the Company diagnoses and predicts the plans to target the therapeutic applications.
Moreover, the clinical services through the Company provide a solid clinical and functional molecular diagnostic test. The bioinformatics and pathology services for evaluating the risk of cancer also leverage the latest technology in personalized medicine for improved health.
The interpace has also commercialized molecular tests, and each test has a clinical evaluation program run for the diagnosis and prognosis of pancreatic cancer from the cysts from a molecule only.
This version of PncraGEN has provided physicians with a snapshot of the limited number of factors. Also, the molecular-based assay helps you to resolve the risk of progression of esophageal cancer. The performance of the test and other potential support also add to the payer reimbursements.
About IDXG Stock:
The Company Interpace Biosciences was established in 1986, and the headquarters are developed in the United States. A financial statement analysis of IDXG Stock indicates that the short-term assets of this Company cover the short-term liabilities.
On the other hand, all the long-term assets of this Company are also exceeding and hence covering the long-term liabilities. Moreover, the IDXG Stock holds the current price of 2.05 US dollars on September 21, 2022.
However, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings with Comerica Bank and BroadOak, and the Company’s dependence on sales and reimbursements from its clinical services are all mentioned in the forward-looking statements.